Rybelsus vs. Farxiga
See how Rybelsus and Farxiga compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Rybelsus is a once-daily oral GLP-1 that lowers blood sugar and reduces cardiovascular risk in type 2 diabetes, while Farxiga is a once-daily SGLT2 inhibitor also approved for heart failure and chronic kidney disease.
Rybelsus commonly causes nausea and other GI side effects, while Farxiga more often causes genital and urinary infections.
Rybelsus needs a step-up dosing schedule over two months, while Farxiga uses a flat dose from day one.
Rybelsus vs. Farxiga Drug Summary
Rybelsus
Rybelsus (semaglutide) is an oral GLP-1 receptor agonist used to control blood sugar in adults with type 2 diabetes and to lower cardiovascular risk in those with existing heart disease. It is taken once daily, starting at 3 mg and increasing over several weeks to a maintenance dose of 7 mg or 14 mg. Some clinicians prescribe it off-label for weight loss.
Farxiga
Farxiga (dapagliflozin) is an oral SGLT2 inhibitor used to control blood sugar in type 2 diabetes, and separately approved to treat heart failure and slow chronic kidney disease progression. It is taken once daily at a fixed dose of 5 mg or 10 mg, with no titration needed. It works by causing the kidneys to remove excess glucose through urine.
Rybelsus vs. Farxiga Side Effects
Rybelsus
Farxiga
Rybelsus vs. Farxiga Dosage
Rybelsus
Farxiga
| STAGE | DOSE | WHEN |
| Starting dose | 3 mg once daily | Days 1-30 |
| Maximum dose | 14 mg once daily | Day 61 onward |
| Dose changes | 2 increases | Every 30 days |
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once daily | At the start |
| Maximum dose | 10 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Rybelsus
| STAGE | DOSE | WHEN |
| Starting dose | 3 mg once daily | Days 1-30 |
| Maximum dose | 14 mg once daily | Day 61 onward |
| Dose changes | 2 increases | Every 30 days |
Farxiga
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once daily | At the start |
| Maximum dose | 10 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Rybelsus vs. Farxiga Indications
Rybelsus
Rybelsus is FDA-approved to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of heart attack, stroke, or cardiovascular death in those with established heart disease. It is not approved for type 1 diabetes or for chronic weight management, though some doctors prescribe it off-label for weight loss.
Blood sugar control in type 2 diabetes
Reduces risk of major cardiovascular events
Off-label use for weight loss
Not approved for type 1 diabetes
Farxiga
Farxiga is FDA-approved for blood sugar control in type 2 diabetes, including children 10 and older, and for reducing hospitalization risk from heart failure. It is also approved to treat heart failure directly and to slow the progression of chronic kidney disease, independent of diabetes status.
Blood sugar control in type 2 diabetes
Heart failure treatment, with or without diabetes
Slows chronic kidney disease progression
Approved for children 10 and older
Rybelsus vs. Farxiga Pros and Cons
Rybelsus
Rybelsus offers GLP-1 benefits in pill form, appealing to people who want to avoid injections. It carries a boxed warning for thyroid tumors seen in animal studies and is not appropriate for anyone with a personal or family history of certain thyroid cancers.
Pros
Oral tablet, no injection needed
Also lowers cardiovascular risk in type 2 diabetes
Often used off-label for weight loss
Same active ingredient as injectable Ozempic
Cons
Common GI side effects like nausea and diarrhea
Boxed warning for thyroid C-cell tumors
Not for those with history of MTC or MEN2
Roughly $998 to $1,029 per month without insurance
Farxiga
Farxiga has a broader label than most diabetes drugs, covering heart failure and chronic kidney disease even in people without diabetes. It requires no dose titration, but it does carry risks tied to how it works, including genital infections and volume depletion.
Pros
Approved for heart failure independent of diabetes
Also slows chronic kidney disease progression
Simple flat dosing with no titration period
Roughly $400 to $785 per month without insurance
Cons
Genital yeast infections are common
Risk of ketoacidosis even with normal blood sugar
Not recommended in severe kidney impairment
Risk of volume depletion and low blood pressure
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.